A Randomized, Double-blind, Placebo-controlled Trial of Banlangen Chongji and Modified Yin Qiao San Formula Used in the Treatment of Subjects with common cold

A Randomized, Double-blind, Placebo-controlled Trial of Banlangen Chongji and Modified Yin Qiao San Formula Used in the Treatment of Subjects with acute upper respiratory tract infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000906

Enrollment

Unknown

Registered

2010-06-24

Start date

2010-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Upper Respiratory Tract Infection

Interventions

A:every 5-10 g / bag a time, three times a day for Banlangen Chongji

every 5-10 g / bag a time, three times a day for Yinqiaosan Variational Formula, it was usually taken with 50 to 100 ml water.

B:The concentration of Both Banlangen and Yinqiaosan are 1/10, and their taking frequency and quantity were the same to that of Intervention Group

C:Every 5 to 10 g / bag a time, three times a day for Banlangen Chongji

every 5 to 10 g / bag a time, three times a day for Yinqiaosan Variational Formula, it was usually taken with 50 to 100 ml water.

D:The concentration of Both Banlangen and Yinqiaosan are 1/10, and their taking frequency and quantity were the same to that of Intervention Group.

Eligibility

Sex/Gender

All

Age

12 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with Wind-fever could of Acute Upper Respiratory Tract Infection regardless of gender, aged 12-602. Wind-fever could of Acute Upper Respiratory Tract Infection is defined as acute nasopharyngitis and classified as wind-fever cold as per Chinese medicine. 3. Patients suffering from wind-fever cold of Acute Upper Respiratory Tract Infection no more than 2 days4. Patients taking not any other medication and receiving no treatment measure.

Exclusion criteria

Exclusion criteria: 1. Patients whose body temperature was higher than 38.5?C when enrolled; 2. Patients who were receiving antibiotics or anti-inflammatory medications; 3. Patients whose onset time has been three days (including the third day); 4. Patients with concurrent pulmonary infection, bronchitis, asthma, and other infectious diseases, cancer, wasting disease, mental illness or other disorders.

Design outcomes

Primary

Measure	Time frame
Inefficiency and Complication Rate;Cure Rat;	—

Secondary

Measure	Time frame
Leucocyte count;Leukocyte classification;Alleviation degree of symptoms every da;	—

Countries

China

Contacts

Public ContactTaixiang Wu

txwutx@hotmail.com+86 28 85422081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026